m-PEG7-Br
CAS No. 104518-25-4
m-PEG7-Br ( —— )
Catalog No. M26976 CAS No. 104518-25-4
m-PEG7-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
Purity : >98% (HPLC)
Size | Price / USD | Stock | Quantity |
50MG | 26 | In Stock |
|
100MG | Get Quote | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product Namem-PEG7-Br
-
NoteResearch use only, not for human use.
-
Brief Descriptionm-PEG7-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
-
Descriptionm-PEG7-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.(In Vitro):PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor(HO)-1; Antifection; NF-κB; NO; NOS; Nrf2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number104518-25-4
-
Formula Weight403.3
-
Molecular FormulaC15H31BrO7
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCOCCOCCOCCOCCOCCOCCOCCBr
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Alendronic Acid
Alendronic acid is a nonhormonal medication?used for osteoporosis osteogenesis imperfecta and several other bone diseases.
-
Alpha-calcium ketogl...
Alpha-calcium ketoglutarate monohydrate is the calcium salt form of Alpha-ketoglutarate, which is involved in the tricarboxylic acid cycle in organisms.
-
Remimazolam
Remimazolam is a benzodiazepine derivative drug as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures.?Remimazolam was found to be both faster acting and shorter lasting than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.?